|Table of Contents|

Prospect of fecal microbiota transplantation combined with PD-L1 inhibitors and chemotherapy in the treatment of triple-negative breast cancer

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2023 06
Page:
1177-1180
Research Field:
Publishing date:

Info

Title:
Prospect of fecal microbiota transplantation combined with PD-L1 inhibitors and chemotherapy in the treatment of triple-negative breast cancer
Author(s):
DONG Tuozhou1; 2; GONG Xue1; LI Dalin1
1.Breast Surgery Ward 1,Harbin Medical University Cancer Hospital,Heilongjiang Harbin 150081,China;2.Department of General Surgery,Jiande Branch,the Second Affiliated Hospital of Zhejiang University,Zhejiang Hangzhou 311600,China.
Keywords:
fecal microbiota transplantation; PD-L1/PD-1; TNBC
PACS:
R737.9
DOI:
10.3969/j.issn.1672-4992.2023.06.040
Abstract:
Compared with other breast cancer subtypes,patients with triple-negative breast cancer (TNBC),regardless of their disease stage,are always considered to have the worst overall survival data.In recent years,PD-L1 inhibitors combined with albumin paclitaxel have made breakthrough progress in the treatment of TNBC,but the side effects of drugs in the treatment process have also greatly restricted the clinical application of chemotherapy,causing it to damage cancer cells and damage human health at the same time.Many scientific research results have confirmed that a balanced intestinal flora can enhance the effect of chemotherapy and reduce its side effects.As a new technology,microbial transplantation has been widely carried out in some medical research institutions at home and abroad in the reconstruction of gastrointestinal microecology.This article reviews the value of microbial transplantation combined with PD-L1 inhibitors and chemotherapy for triple negative breast cancer.

References:

［1］SCHMID P,ADAMS S,RUGO HS,et al.Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable,locally advanced or metastatic triple-negative breast cancer (IMpassion130):Updated efficacy results from a randomised,double-blind,placebo-controlled,phase 3 trial［J］.Lancet Oncol,2020,21(1):44-59.
［2］WANG XR,LIU YP.PD-L1 expression in tumor infiltrated lymphocytes predicts survival in triple-negative breast cancer［J］.Pathol.Res.Pract,2020,216(3):1-5.
［3］GARUFI G,PALAZZO A,PAIRS I,et al.Neoadjuvant therapy for triple-negative breast cancer:Potential predictive biomarkers of activity and efficacy of platinum chemotherapy,PARP-and immune-checkpoint-inhibitors［J］.Expert Opin Pharmacother,2020,21(6):1-13.
［4］EMENS LA,CRUZ C,EDER JP,et al.Long-term clinical outcomes and biomarker analyses of atezolizumab therapy for patients with metastatic triple-negative breast cancer:A phase 1 study［J］.JAMA Oncol,2019,5(1):74-82.
［5］NARAYAN P,WAHBY S,GAO JJ,et al.FDA approval summary:Atezolizumab plus paclitaxel protein-bound for the treatment of patients with advanced or metastatic TNBC whose tumors express PD-L1［J］.Clin Cancer Res,2020,26(10):1-10.
［6］SCHMID P,ADAMS S,RUGO HS,et al.Atezolizumab and Nab-Paclitaxel in advanced triple-negative breast cancer［J］.N Engl J Med，2018,379(22):2108-2121.
［7］ALEXANDER JL,WILSON ID,TEARE J,et al.Gut microbiota modulation of chemotherapy efficacy and toxicity ［J］.Nat Rev Gastroenterol Hepatol,2017,14(6):356-365.
［8］LE BASTARD Q,WARD T,SIDIROPOULOS D,et al.Fecal microbiota transplantation reverses antibiotic and chemotherapy-induced gut dysbiosis in mice［J］.Sci Rep,2018,8(1):1-11.
［9］AZIM HA,GHOSM M,OUALLA K,et al.Personalized treatment in metastatic triple-negative breast cancer:The outlook in 2020［J］.Breast J,2020,26(1):69-80.
［10］AKIKI M,HADDAD FG,KOURIE HR,et al.PD-L1 an unavoidable biomarker in advanced triple-negative breast cancer［J］.Biomark Med,2019,13(18):1539-1541.
［11］VORMEHOR M,DIKEN M,BOEGEL S,et al.Mutanome directed cancer immunotherapy［J］.Curr Opin Immunol,2016,39:14-22.
［12］Cancer Genome Atlas Network.Comprehensive molecular portraits of human breast tumours［J］.Nature,2012,490(7418):61-70.
［13］TURNER NC,TELLI ML,RUGO HS,et al.BRCA1/2A phase II study of talazoparib after platinum or cytotoxic nonplatinum regimens in patients with advanced breast cancer and germline mutations (ABRAZO)［J］.Clin Cancer Res,2019,25(9):2717-2724.
［14］ADAMS S,SCHMID P,RUGO HS,et al.Pembrolizumab monother apy for previously treated metastatic triple-negative breast cancer:Cohort A of the phase II KEYNOTE-086 study［J］.Ann Oncol,2019,30(3):397-404.
［15］YARDLEY DA,COLEMAN R,CONTE P,et al.nab-Paclitaxel plus carboplatin or gemcitabine versus gemcitabine plus carboplatin as first-line treatment of patients with triple-negative metastatic breast cancer:Results from the tnAcity trial［J］.Ann oncol,2018,29(8):1763-1770.
［16］ADAMS S,DIERAS V,BARRIOS CH,et al.Patient-reported outcomes from the phase III IMpassion130 trial of atezolizumab plus nab-paclitaxel in metastatic triple-negative breast cancer［J］.Ann Oncol,2020,31(5):582-589.
［17］ TAKI J,HIGUCHI T,SUMIYA H,et al.Prediction of myocutaneous adverse side effect due to intra-arterial chemotherapy by intra-arterial (99m)Tc-macroaggregated albumin administration in patients with bone and soft-tissue tumors［J］.J Nucl Med,2002,43(11):1452-1456.
［18］YU FAN,ZHAOMIN YANG,MING WAN，et al.Effects of moxibustion therapy on preventing and treating side effects from chemotherapy of malignant tumor patients ［J］.Journal of Acupuncture and Tuina Science,2011,9(6):351-353.
［19］ALLALI I,DELGADO S,MARRON PI,et al.Gut microbiome compositional and functional differences between tumor and non-tumor adjacent tissues from cohorts from the US and spain［J］.Gut Microbes,2015,6(3):161-172.
［20］SHEN S,LIM G,YOU Z,et al.Gut microbiota is critical for the induction of chemotherapy-induced pain［J］.Nat Neurosci,2017,20(9):1213-1216.
［21］WANG L,TANG L,FENG Y,et al.A purified membrane protein from Akkermansia muciniphila or the pasteurised bacterium blunts colitis associated tumourigenesis by modulation of CD8+ T cells in mice［J］.Gut,2020,23(1):107-113.
［22］MENEES SB,MANEERATTANNAPORN M,KIM HM,et al.The efficacy and safety of rifaximin for the irritable bowel syndrome:A systematic review and meta-analysis［J］.Am J Gastroenterol,2012,107(1):28-35.
［23］KELLY BJ,TEBAS P.Clinical practice and infrastructure review of fecal microbiota transplantation for clostridium difficile infection［J］.Chest,2018,153(1):266-277.
［24］VIAUD S,SACCHERI F,MIGNOT G,et al.The intestinal microbiota modulates the anticancer immune effects of cyclophosphamide［J］.Science,2013,342(6161):971-976.
［25］OUWEHAND AC.A review of dose-responses of probiotics in human studies［J］.Benef Microbes,2017,8(2):143-151.
［26］WANG Y,WIESNOSKI DH,HELMINKBA,et al.Fecal microbiota transplantation for refractory immune checkpoint inhibitor-associated colitis［J］.Nat Med,2018,24(12):1804-1808.
［27］BOTTICELLI A,VERNOCCHI P,MARINI F,et al.Gut metabolomics profiling of non-small cell lung cancer (NSCLC) patients under immunotherapy treatment［J］.J Transl Med,2020,18(1):1-10.
［28］ROUTY B,LE CHATELIER E,DEROSA L,et al.Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors［J］.Science,2018,359(6371):91-97.
［29］ JIN Y,DONG H,XIA L,et al.The diversity of gut microbiome is associated with favorable responses to anti-programmed death 1 immunotherapy in Chinese patients with NSCLC［J］.J Thorac Oncol,2019,14(8):1378-1389.
［30］WU H,ZHENG X,PAN T,et al.Dynamic microbiome and metabolome analyses reveal the interaction between gut microbiota and anti-PD-1 based immunotherapy in hepatocellular carcinoma ［J］.International Journal of Cancer,2022,151(8):1321-1334.
［31］XU L,QI Y,JIANG Y,et al.Crosstalk between the gut microbiome and clinical response in locally advanced thoracic esophageal squamous cell carcinoma during neoadjuvant camrelizumab and chemotherapy［J］.Annals of Translational Medicine,2022,10(6):325.
［32］ SPENCER CN,MCQUADE JL,GOPALAKRISHNAN V,et al.Dietary fiber and probiotics influence the gut microbiame and melanoma immunotherapy response［J］.Science,2021,374(6575):1632-1640.

Memo

Memo:
-
Last Update: 1900-01-01